Search Clinical Trials

Clinical Trials Search Results

The results of your search are listed below. To view the details of a trial or study, click on the see details >> link. Or start a new search.

Searched for: Lung Cancer

16 results total

A Phase II Study of Intermittent Gleevec® (Imatinib mesylate) and Weekly Paclitaxel in Patients Aged 70 or Older with Advanced Non-Small Cell Lung Cancer

[UW]

Principal Investigator: Renato Martins, MD, MPH

Study Number: 6137

Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer

[UW]

Principal Investigator: Renato Martins, MD, MPH

Study Number: 6228

FDG-PET Based Chemotherapy Selection for Metastatic Non-Small Cell Lung Cancer

[UW]

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 6566

Phase I/II Clinical Trial Evaluating the Use of Vorinostat Combined with Paclitaxel and Radiotherapy in Patients with Inoperable Stage III Non-Small Cell Lung Cancer Unable to Tolerate Cisplatin

[UW]

Principal Investigator: Shilpen Patel, MD

Study Number: 6600

A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (<=2 cm) Peripheral Non-Small Cell Lung Cancer

Principal Investigator: Frederick Appelbaum, MD

Study Number: CTSU C140503

A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without bevacizumab for Patients With completely Resected Stage IB (> or = 4 cm) ? IIIA Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Frederick Appelbaum, MD

Study Number: CTSU E1505

Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung Cancer

Principal Investigator: Frederick Appelbaum, MD

Study Number: CTSU E5597

A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

Principal Investigator: Frederick Appelbaum, MD

Study Number: SWOG 0222

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloaveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features

Principal Investigator: Frederick Appelbaum, MD

Study Number: SWOG 0635

A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and bevacizumab (Rhumab Vegf; NSC-704865) in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas

Principal Investigator: Frederick Appelbaum, MD

Study Number: SWOG 0636

Displaying first 10 of 16 total results. Click to view all 16 results.

Search Options

OR

Select a disease from the list below:

Limit results to studies enrolling:
Both Adults & Pediatrics Adults Pediatrics

OR

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Terms of Use and Privacy Policy

Fred Hutchinson Cancer Research Center
1100 Fairview Ave. N. PO Box 19024 Seattle, WA 98109
©2009 Fred Hutchinson Cancer Research Center, a nonprofit organization.
Terms of Use & Privacy Policy.

Patient Information

Cancer Treatment

Search Clinical Trials

Search Clinical Trials